DexCom, Inc. (NASDAQ:DXCM) insider Terrance H. Gregg sold 10,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total value of $568,600.00. Following the sale, the insider now directly owns 484,559 shares in the company, valued at approximately $27,552,024.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
DexCom, Inc. (NASDAQ DXCM) traded down $0.04 during midday trading on Thursday, hitting $56.28. The company had a trading volume of 1,232,609 shares, compared to its average volume of 2,046,800. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. DexCom, Inc. has a 12 month low of $42.62 and a 12 month high of $86.32. The firm has a market cap of $4,890.00, a P/E ratio of -98.74 and a beta of 0.31.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.11. DexCom had a negative return on equity of 20.44% and a negative net margin of 7.21%. equities research analysts anticipate that DexCom, Inc. will post -0.64 EPS for the current year.
A number of equities research analysts have weighed in on DXCM shares. Northland Securities started coverage on DexCom in a report on Tuesday, September 26th. They issued an “outperform” rating and a $85.00 target price on the stock. JPMorgan Chase & Co. downgraded DexCom from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $93.00 to $71.00 in a report on Thursday, September 28th. Citigroup downgraded DexCom from an “outperform” rating to a “market perform” rating in a report on Thursday, September 28th. Jefferies Group reaffirmed a “buy” rating and issued a $91.00 target price on shares of DexCom in a report on Thursday, September 28th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $76.00 target price (down previously from $85.00) on shares of DexCom in a report on Thursday, September 28th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company. DexCom has an average rating of “Buy” and a consensus target price of $68.50.
COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (DXCM) Insider Sells $568,600.00 in Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/18/dexcom-inc-dxcm-insider-sells-568600-00-in-stock.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.